Warm Autoimmune Hemolytic Anemia Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Warm Autoimmune Hemolytic Anemia Market is segmented By Drug Class, Immunosuppressive agents, Monoclonal antibodies, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Warm Autoimmune Hemolytic Anemia Market Overview

Global Warm Autoimmune Hemolytic Anemia Market is expected to reach at a high CAGR during the forecast period 2023-2030.

The majority of cases of autoimmune hemolytic anaemia (AIHA), 60 to 70 percent, are warm autoimmune hemolytic anaemia (WAIHA). It is typically caused by an autoantibody to immunoglobulin G (IgG), which may activate complement (C) if it is high titer or if IgG1 and IgG3 subclasses are common. The direct antiglobulin test (DAT), which is the cornerstone of diagnosis, may be positive with anti-IgG antisera (70% of all wAIHA) or anti-IgG plus C at low titer.

The accuracy and timeliness of diagnosing WAIHA have increased due to developments in laboratory techniques including flow cytometry and serologic assays. The WAIHA therapy landscape is changing, and targeted medicines that try to change the underlying immunological dysregulation are gaining greater acceptance. An increasing amount of attention is being paid to symptom management, psychosocial support, and patient education as ways to enhance the quality of life for people with WAIHA.

Warm Autoimmune Hemolytic Anemia Market Scope

For more details on this report - Request for Sample

Warm Autoimmune Hemolytic Anemia Market Dynamics

The Rise of Clinical Trials on WAIHA treatment

For WAIHA, there still lacks an approved treatment. There is still a significant unmet medical demand for brand-new, secure, and efficient treatments for AIHA. Novel targeted therapeutics focusing on the underlying mechanism of hemolytic anaemia and the treatment of resistant disease have been developed as a result of recent developments in understanding the pathophysiology of immunologic mechanisms that result in red cell destruction. Therefore, companies began working on drug development, which contributes to the market's expansion.

For instance, in March 2022, top-line efficacy and safety data from the forward Phase 3 clinical study, a worldwide, multi-center, randomised, double-blind, placebo-controlled trial of fostamatinib in patients with warm autoimmune hemolytic anaemia (WAIHA), were released by Pharmaceuticals, Inc. The primary efficacy endpoint of sustained haemoglobin response in the entire study population was not statistically significant in the trial. The business is still certain that fostamatinib can help people with wAIHA, a group with a critical unmet medical need. The market's expansion is accelerated by the above-mentioned factors.

Increase in Demand for the Development of Combination Therapies

The most common treatment for warm-antibody AIHA is corticosteroids, however in cases of cold agglutinin disease, the underlying clonal B-cell proliferation or the traditional complement activation route are targeted. In the past one to two decades, a number of new established or exploratory medications and treatment plans have emerged, improving therapy possibilities but also creating obstacles regarding how to choose the appropriate course of action for certain patients.

For instance, in the majority of individuals with WAIHA, prednisolone (or prednisone), monotherapy is advised as the first line of treatment. The low chance of long-lasting remission upon tapering and discontinuation (30-40% after 1 year) is concerning, nevertheless, especially in individuals who are severely afflicted (98–100). Patients may spend years being kept on unnecessarily high dosages of steroids in clinical practise.

The upfront addition of rituximab (either 4 infusions of 375 mg/m2 at one-week intervals or 2 infusions of 1000 mg fixed dose at two-week intervals) was assessed in two prospective, randomised studies. The outcomes were quite similar, with patients who received the combo upfront experiencing twice as many long-term responses as those who received prednisolone alone. As a result, the worldwide consensus committee has advised that first-line rituximab plus prednisolone combination therapy be explored for severely anaemic patients (defined as haemoglobin [Hb] 8 g/dL). As a result, combo medications aid in accelerating market expansion.

Limited Treatment Options for the WAIHA

The complexity of the disease, its variation between people, and the difficulties in treating autoimmune hematologic disorders are some of the causes of WAIHA limited therapeutic choices. Being diverse, WAIHA can manifest itself in many ways in different people. 

The underlying causes, seriousness, and treatment outcome can be very different. It is difficult to create a therapeutic strategy that works for everyone because of all of this variation. Corticosteroids and immunosuppressive medicines, among other treatments for WAIHA, can have serious side effects. It can be difficult to balance the advantages of these treatments with their possible drawbacks, particularly when the condition is being managed over the long term.

Warm Autoimmune Hemolytic Anemia Market Segment Analysis

The global warm autoimmune hemolytic anemia market is segmented based on drug class, route of administration, distribution channel and region.

Corticosteroids Play a Critical Part in the Treatment of WAIHA

Prednisone is one of many powerful corticosteroids that have immunosuppressive properties. They function by reducing immune system activity, including the development of autoantibodies, which are antibodies that attack the patient's own red blood cells. Autoantibodies in WAIHA result in anaemia by destroying red blood cells. Corticosteroids can aid in lowering the synthesis and activity of these autoantibodies by inhibiting the immunological response. In WAIHA, where prompt treatment is frequently required to address severe anaemia and related symptoms such weariness, pallor, and shortness of breath, corticosteroids typically take effect rather fast.

While adding rituximab should be considered early in severe instances and in the absence of a quick response to steroids, corticosteroids remain the first-line treatment for warm-AIHA. Patients with cold agglutinin disease who need treatment should first try rituximab, either with or without bendamustine. 

The best first-line treatment for warm AIHA, particularly the IgG-related variety, is corticosteroids. By inhibiting the mononuclear phagocytic Fc gamma receptor, their action is linked to a reduction in hemolysis and causes a quick recovery within 24 to 48 hours. Additionally, they have a delayed detrimental impact on the generation of autoantibodies, although this takes time—a few weeks. Thus, the previously mentioned factors aid in accelerating segment expansion.

Warm Autoimmune Hemolytic Anemia Market Geographical Share

Rising Healthcare Technologies and Product Launches in the North American Region

The warm autoimmune hemolytic anaemia market is expected to be significantly impacted by North America, with the United States being the region's largest contributor. One of the more prevalent diseases in modern times is warm autoimmune hemolytic anaemia. Additionally, the incidence of diseases and the development of modern healthcare technology both contribute to the region's growth.

For instance, North America has a diversified cultural population, and this population has an impact on healthcare. Both countries' healthcare systems have to fulfill the demands of a variety of cultural and ethnic groups, which can have an impact on healthcare policy and the provision of care. Healthcare in both U.S. and Canada countries is significantly impacted by the legal and regulatory systems in place. 

In the US, both the federal and state governments have strict regulations governing healthcare, and there are intricate relationships between the public and private sectors. In Canada, the federal government regulates healthcare more heavily than the provincial and territorial governments that are in charge of providing services.

Additionally, WAIHA and other autoimmune diseases may have a genetic basis. A person's susceptibility to autoimmune diseases may be influenced by specific hereditary variables. These genetic components are present in people all around the world and are not exclusive to North America. People from different racial, ethnic, and cultural backgrounds as well as different genetic dispositions inhabit North America. Different groups may be more or less susceptible to autoimmune conditions, such as WAIHA. Thus, all of these indicates fuel the region's growth.

COVID-19 Impact Analysis

The COVID-19 epidemic put enormous strain on the world's healthcare systems. Many times, COVID-19 cases overflowed hospitals and healthcare institutions, disrupting the care and treatment of patients with other medical illnesses, such warm AIHA. There may have been delays in the diagnosis and treatment of some patients. Priorities in healthcare underwent a considerable shift throughout the epidemic towards monitoring and controlling COVID-19. 

This change may have affected access to new medicines as well as research, development, and attention for ailments like Warm AIHA. Telemedicine and remote monitoring solutions are being more commonly used to reduce the number of in-person medical appointments and lower the danger of contracting the virus. This might have affected how Warm AIHA patients received treatment and follow-up, possibly resulting in modifications to treatment modalities.

Key Developments

• On October 10, 2022, HUTCHMED (China) Limited has announced that a Phase II/III trial of sovleplenib has been started in China for adult patients with warm antibody autoimmune hemolytic anaemia ("wAIHA"). With few available options for treatment, wAIHA is an autoimmune condition that can cause anaemia. On September 30, 2022, the first patient received their first dose. This clinical experiment is randomised, double-blind, and placebo-controlled. In the Phase II stage of the study, sovleplenib's preliminary efficacy and safety are being assessed in adult wAIHA patients.
• On May 25, 2023, Novartis, a Phase 3 randomised, double-blind, study to evaluate the safety and efficacy of Ianalumab (VAY736) versus placebo in patients with Warm Autoimmune Hemolytic Anaemia (wAIHA) who have failed at least one line of treatment. In patients with warm autoimmune hemolytic anaemia who had at least one line of treatment fail, the aim of this trial is to compare the efficacy and safety of ianalumab versus placebo.

Warm Autoimmune Hemolytic Anemia Market Companies

The major global players in the market include Novartis AG, F. Hoffmann-La Roche Ltd, Rigel Pharmaceuticals, Alexion Pharmaceuticals, Inc., Momenta Pharmaceuticals Immunovant, Incyte Corporation, Teva Pharmaceutical Industries Ltd, Sanofi, Apellis Pharmaceuticals, Inc and among others.

Why Purchase the Report?

• To visualize the global warm autoimmune hemolytic anemia market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of warm autoimmune hemolytic anemia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Warm Autoimmune Hemolytic Anemia market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies